EMMA Stock Overview
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
Capture your thoughts, links and company narrative
Emmaus Life Sciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.31|
|52 Week High||US$0.60|
|52 Week Low||US$0.071|
|1 Month Change||-1.59%|
|3 Month Change||-18.42%|
|1 Year Change||-16.22%|
|3 Year Change||-80.75%|
|5 Year Change||n/a|
|Change since IPO||-96.84%|
Recent News & Updates
|EMMA||US Pharmaceuticals||US Market|
Return vs Industry: EMMA underperformed the US Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: EMMA underperformed the US Market which returned -0.7% over the past year.
|EMMA Average Weekly Movement||14.3%|
|Pharmaceuticals Industry Average Movement||10.6%|
|Market Average Movement||6.5%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: EMMA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: EMMA's weekly volatility has decreased from 26% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.
Emmaus Life Sciences, Inc. Fundamentals Summary
|EMMA fundamental statistics|
Is EMMA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EMMA income statement (TTM)|
|Cost of Revenue||US$2.01m|
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
|Earnings per share (EPS)||-0.24|
|Net Profit Margin||-57.56%|
How did EMMA perform over the long term?See historical performance and comparison